Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782780 | 1.00 | CNR2 (0.48) | CNR2ADRA1DCA12CA1CA2 | |
| SCHEMBL1608385 | 0.86 | HDAC3 (0.56) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL1608387 | 0.86 | HDAC3 (0.56) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL1608228 | 0.85 | HDAC1 (0.60) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL1608231 | 0.85 | HDAC1 (0.60) | HDAC8HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL4673488 | 0.84 | CA12 (0.48) | CNR2ADRA1DCA12CA1CA2 | |
| SCHEMBL4673481 | 0.84 | CA12 (0.48) | CNR2ADRA1DCA12CA1CA2 | |
| SCHEMBL16475182 | 0.80 | HCAR2 (0.41) | CA1CA2HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL1608721 | 0.79 | HCAR2 (0.40) | CA12CA1CA2CA9HDAC8 | |
| SCHEMBL1608722 | 0.79 | HCAR2 (0.40) | CA12CA1CA2CA9HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | CNR2 89/4885ADRA1D 2719/4885CA12 415/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | CNR2 613/4885ADRA1D 882/4885CA12 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.